Assessment of Helicobacter pylori eradication in patients on NSAID treatment by Vonkeman, H.E. et al.
Vonkeman et al. BMC Gastroenterology 2012, 12:133
http://www.biomedcentral.com/1471-230X/12/133RESEARCH ARTICLE Open AccessAssessment of Helicobacter pylori eradication in
patients on NSAID treatment
Harald E Vonkeman1*, HTJI deLeest2†, MAFJ van deLaar1, J vanBaarlen3, KSS Steen2, WF Lems2, JWJ Bijlsma4,
EJ Kuipers5, HHML Houben6, M Janssen7 and BAC Dijkmans2Abstract
Background: In this post-hoc analysis of a randomized, double blind, placebo controlled trial, we measured the
sensitivity and specificity of Helicobacter pylori IgG-antibody titer changes, hematoxylin and eosin (H&E) stains,
immunohistochemical (IHC) stains and culture results in NSAID using patients, following H. pylori eradication
therapy or placebo.
Methods: 347 NSAID using patients who were H. pylori positive on serological testing for H. pylori IgG-antibodies
were randomized for H. pylori eradication therapy or placebo. Three months after randomization, gastric mucosal
biopsies were taken for H. pylori culture and histological examination. At 3 and 12 months, blood samples were
taken for repeated serological testing. The gold standard for H. pylori infection was based on a positive culture or
both a positive histological examination and a positive serological test. Sensitivity, specificity and receiver operating
curves (ROC) were calculated.
Results: H. pylori eradication therapy was successful in 91% of patients. Culture provided an overall sensitivity of
82%, and 73% after eradication, with a specificity of 100%. Histological examination with either H&E or IHC stains
provided sensitivities and specificities between 93% and 100%. Adding IHC to H&E stains did not improve these
results. The ROC curve for percent change in H. pylori IgG-antibody titers had good diagnostic power in identifying
H. pylori negative patients, with an area under the ROC curve of 0.70 (95 % CI 0.59 to 0.79, P= 0.085) at 3 months
and 0.83 (95% CI 0.76 to 0.89, P< 0.0001) at 12 months. A cut-off point of at least 21% decrease in H. pylori
IgG-antibody titers at 3 months and 58% at 12 months provided a sensitivity of 64% and 87% and a specificity of
81% and 74% respectively, for successful eradication of H. pylori.
Conclusions: In NSAID using patients, following H. pylori eradication therapy or placebo, histological examination of
gastric mucosal tissue biopsies provided good sensitivity and specificity ratios for evaluating success of H. pylori
eradication therapy. A percentual H. pylori IgG-antibody titer change has better sensitivity and specificity than an
absolute titer change or a predefined H. pylori IgG-antibody titer cut-off point for evaluating success of H. pylori
eradication therapy.Background
Helicobacter pylori (H. pylori) infection has been shown
to be related to the development of peptic ulcer disease,
chronic gastritis, MALT lymphoma and gastric cancer
[1-4]. Accurate diagnosis of H. pylori infection has clin-
ical consequences as H. pylori eradication improves* Correspondence: h.vonkeman@mst.nl
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distribution, and reproduction in any mediumoutcome and recurrence of peptic ulcer disease. H. pyl-
ori infection can be detected using non-invasive tests
such as serological tests, 13C-urea breath test and stool
tests, and invasive tests requiring endoscopically
obtained gastric mucosal tissue biopsies, such as tissue
culture, examination of histological stains and the rapid
urease test. Serological tests based on the detection of
antibodies to H. pylori have been shown to have high
sensitivity and are therefore useful in screening for H.
pylori infection [5-7]. However, because serological tests
merely detect an immune response, they do not discrim-
inate between current or previous infection. H. pyloritral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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flammatory cell infiltration, which in turn gives rise to a
serological response, in which H. pylori specific anti-
bodies are almost always detectable [8,9]. After success-
ful H. pylori eradication therapy, the level of H. pylori
specific antibodies decreases progressively over a period
of several months, possibly parallel to the slowly healing
inflammation of the gastric mucosa [10]. As a result,
evaluating success of H. pylori eradication therapy using
repeated serological tests has only been shown to be
useful if a period of several months is maintained be-
tween tests [11-13].
Culture of H. pylori in biopsy specimens has very high
specificity and allows testing for antibiotic susceptibility
but has relatively low sensitivity and is labour-intensive
[14]. Histological identification of H. pylori in biopsy
specimens has long been considered to be the clinical
standard for the diagnosis of H. pylori infection. A high
density of H. pylori is readily apparent on routine
hematoxylin and eosin (H&E) stains but detection of a
lower density of bacteria may require additional staining
techniques [15]. H. pylori is more easily visualised with
immunohistochemical H. pylori antibody stains than
with the standard H&E staining. However, the use of
immunohistochemical (IHC) stains adds time and ex-
pense to the diagnostic evaluation for H. pylori and is
therefore not routinely performed.
The interaction between H. pylori infection and the
use of non-steroidal anti-inflammatory drugs (NSAIDs)
in the development of gastroduodenal ulcers remains
unclear. In a meta-analysis of 16 endoscopic studies in
NSAID users from various countries, uncomplicated
gastric ulcer disease was twice as common in H. pylori
positive patients as in H. pylori negative patients [16].
However, the rate of H. pylori infection in patients with
NSAID associated gastric ulcers is significantly lower
than in those with non-NSAID associated gastric ulcers
[17]. Furthermore, while eradication of H. pylori infec-
tion in NSAID-naïve patients prior to NSAID therapy
reduces the risk of ulcer development, it does not do so
in current NSAID users [18-20]. This was also con-
firmed in a recent randomized, double blind, placebo
controlled clinical trial, in which we found that eradica-
tion of H. pylori infection did not reduce the incidence
of endoscopic gastroduodenal ulcers in H. pylori sero-
positive patients currently taking NSAIDs for rheumatic
diseases [21].
H. pylori infection has been shown to induce cyclooxy-
genase (COX)-2 expression in the gastric mucosa, which
persists during active H. pylori infection [22-25]. It has
been suggested that COX-2 plays an immunosuppressive
role in H. pylori gastritis [26]. Conversely, in H. pylori
infected mice, NSAID treatment has been shown to sig-
nificantly decrease the degree of gastric inflammation[27]. It is therefore possible that in patients with H. pyl-
ori infection, concurrent NSAID treatment may affect
levels of gastric inflammation and may consequently
affect the serological response. While several studies
have investigated the time course of H. pylori antibody
titers after H. pylori eradication therapy, none have been
conducted in NSAID users [9,11-13,28].
This study presents a post-hoc investigation into H.
pylori IgG-antibody titer changes following H. pylori
eradication therapy in NSAID users. In patients partici-
pating in the before mentioned H. pylori eradication in
NSAID users trial, we measured H. pylori IgG-antibody
titers and titer changes in order to diagnose successful
H. pylori eradication [29]. We further compared H. pyl-
ori IgG-antibody titers, H&E stains, IHC stains and H.
pylori culture results in follow-up biopsies from H. pyl-
ori-positive NSAID-users randomized to eradication
treatment or placebo, to determine the sensitivity and
specificity of these different methods in NSAID users.
Furthermore, we determined whether adding IHC stains
to H&E stains improves the histological identification of
H. pylori in these patients.
Methods
Study design
The methods of the primary randomized, double blind,
placebo controlled clinical trial have been previously
described in more detail21. Between May 2000 and June
2002, patients between the ages of 40 and 80 years with
a rheumatic disease requiring NSAID treatment, were
recruited and included in the study if tested positive for
H. pylori on serological testing. During the study, no
change in NSAID-therapy was permitted, but there was
no restraint on other medication. Exclusion criteria were
previous H. pylori eradication therapy and severe con-
comitant disease.
After stratification by concurrent use of gastroprotec-
tive agents (proton pump inhibitors, H2 receptor
antagonists or misoprostol, but not prokinetics, or anta-
cids), patients were randomly assigned to receive either
H. pylori eradication therapy with omeprazole 20 mg,
amoxycillin 1000 mg, and clarithromycin 500 mg (OAC)
twice daily for 7 days or placebo. Patients with an allergy
for amoxycillin were randomized in a separate stratum
to receive omeprazole 20 mg, metronidazol 500 mg and
clarithromycin 250 mg (OMC) or placebo therapy twice
daily for one week. Randomization to consecutive pa-
tient numbers was done in proportions of 1:1, in blocks
of four from a computer-generated list. The study cen-
ters were provided with individually sealed packages
containing the treatment for each patient. Each centre
received entire blocks to be used sequentially. Rheuma-
tologists were not practicing in more than one center.
The study medication was given in a double blind,
Vonkeman et al. BMC Gastroenterology 2012, 12:133 Page 3 of 8
http://www.biomedcentral.com/1471-230X/12/133double dummy manner. Active and placebo preparations
were identical in appearance. The employees of the VU
University Medical Center pharmacy who packaged the
medication only knew the assignment. It was disclosed
to the treating physician only in case of emergency. All
study personnel and participants were blinded to treat-
ment assignment for the duration of the study.
After 3 months patients underwent gastroduodenal
endoscopy, during which 4 antrum biopsies and 4 cor-
pus biopsies were taken for culture and histological
examination. After 3 and 12 months, blood samples
were taken for repeated serological testing. Immunohis-
tochemical staining was only available for a subset of
patients recruited at the Medisch Spectrum Twente hos-
pital in Enschede, the Netherlands. The study protocol
was approved by the Institutional Ethical Review Board
of all participating hospitals and all patients gave written
informed consent.
Serology
Serological testing for H. pylori IgG-antibodies was per-
formed using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (PylorisetW new
EIA-G, Orion Diagnostica, Espoo, Finland). Results
were considered positive if the antibody titers were ≥250
International Units per mL (IU/mL), according to the
manufacturer’s guidelines. This assay has been assessed,
in a population similar to the population in the presented
trial, and has proven a sensitivity and specificity in the
Netherlands of 98-100% and 79-85%, even in patients on
acid suppressive therapy [11,30,31].
Culture
Biopsy specimens of corpus and antrum taken during
endoscopy were inoculated onto Columbia agar (Becton
Dickinson, Cockeysville, MD, USA) with 10% lysed horse
blood (Bio Trading, Mijdrecht, The Netherlands), and
onto Columbia agar with H. pylori selective supplement
(Oxoid, Basingstoke, UK). Media were then incubated
for 72 hours at 37°C under microaerophilic conditions
(5% O2, 10% CO2 and 85% N2). The isolated colonies of
H. pylori were identified by Gram stain showing spiral-
shaped Gram-negative rods, producing urease rapidly,
with positive catalase and oxidase tests.
Histology
Biopsy specimens were stained for Hematoxylin and
Eosin (H&E) according to the standard procedure. For
immunohistochemical (IHC) staining, the slides were
heated in an autoclave (Kavoklave, Prestige Medical Ltd,
UK) in a citric-acid solution (pH= 6 to 121–126°C dur-
ing 30 minutes for antigen retrieval. The slides were
then incubated in a Shandon Sequenza Immunostaining
Center (Thermo Electron Corporation, the Netherlands)with a polyclonal rabbit IgG anti-Helicobacter pylori
antibody (DakoCytomation, Denmark, dilution 1:300),
followed by biotinylated goat anti-polyvalent antibody
(LabVision Corporation, USA), strepavidin peroxidase
(LabVision Corporation, USA) and Liquid DAB+ substrate
chromogen system (DakoCytomation, Denmark), and
counterstained with hematoxylin.
All stained biopsy specimens of corpus and antrum
taken during endoscopy were examined by a single ex-
pert pathologist who was blinded for clinical data, treat-
ment allocation and other test results.
Gold standard definition
As the gold standard for H. pylori infection in this study,
at 3 months a patient was defined as being H. pylori
positive on the basis of a positive culture for H. pylori
or, in the case of a negative culture, a positive examin-
ation of either H&E or IHC stains in combination with
H. pylori IgG-antibody titers persistently ≥ 250 IU/mL.
At 12 months, a patient was defined as being H. pylori
positive on the basis of a positive culture for H. pylori
or, in the case of a negative culture, a positive examin-
ation of either H&E or IHC stains in biopsy samples at
3 months in combination with H. pylori IgG-antibody
titers persistently ≥ 250 IU/mL at 12 months.
Statistical analysis
Continuous variables with a normal distribution were
expressed as mean with standard deviation (SD), and
continuous variables with a non-normal distribution as
median with interquartile range (IQR). Differences be-
tween groups were analysed using Students t-test,
Mann–Whitney U test, Pearson’s Chi-square test or
Fisher’s Exact test in case of low expected values. For all
analyses P < 0.05, two sided, was considered significant.
All analyses were performed with SPSS for Windows,
version 19.0 (SPSS, Chicago, IL, USA). Receiver Operat-
ing Characteristic (ROC) curves and likelihood ratios
were analysed with MedCalc for windows, version
12.1.3.0. Differences in the proportions of patients
were analyzed with 95% confidence interval using the
Confidence Interval Analysis software for Windows
(version 2.2.0).
Results
A total of 347 patients were included in the present
study. The treatment groups (172 patients in the eradi-
cation group and 175 patients receiving placebo) were
similar in terms of demographics, rheumatic disease,
NSAIDs and other drug use. Our eligibility criteria
resulted in a study group with mainly inflammatory
rheumatic diseases (rheumatoid arthritis 61%, spondy-
loarthropathy 8%, psoriatic arthritis 7%, osteoarthritis
9%, other 15%). The most commonly used NSAIDs were
Table 2 Results of the sensitivity, specificity, positive
predictive value (PPV) and negative predictive value
(NPV) of each test; for the total study group and
differentiated for preceding H. pylori eradication
therapy or placebo
Test Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Culture
Total 82 100 100 87
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The mean age was 60 years (SD 10), 61% was female.
Twenty-two patients had a known allergy for amoxicillin
and received metronidazole instead (10 patients) or pla-
cebo (12 patients). Forty-eight percent used a gastropro-
tective drug (7% H2 receptor antagonists (H2RA), 37%
proton pump inhibitors (PPI), 7% misoprostol, 3% used
a combination of these).
At baseline, Anti-H. pylori IgG antibodies were present
in all 347 patients (median titre 1689 (IQR 700–3732).
At three months, data on both culture and histology
were available in 305 patients; 152 in the eradication
group and 153 in the placebo group. In two cases only
culture data were available and in 1 case only histology
was available. All three cases met the criteria for H. pyl-
ori-positivity and were found in the placebo group. A
total of 32 patients (with no significant differences be-
tween eradication and placebo groups) refused the 3-
month endoscopy, withdrew informed consent, or could
not undergo endoscopy because of adverse events. Seven
patients used anticoagulant therapy, ruling out biopsy
sampling in accordance with the study protocol, and in
one patient no biopsy specimens could be obtained be-
cause of discomfort requiring early completion of the
procedure.
The results of H. pylori detection by each of the differ-
ent tests are shown in Table 1. Out of the 152 patients
who had been treated with H. pylori eradication therapy,
141 (93%) had a negative culture, and of the 153 patients
who had been receiving placebo, 54 (35%) had a negative
culture (P < 0.001). Out of the 152 patients who had
been treated with H. pylori eradication therapy, 133
(88%) had a negative H&E stain, compared to 41 (27%)
of the 153 patients who had been receiving placebo
(P < 0.001). In the subgroup (with statistically similarTable 1 Results of H. pylori detection by each test
Test Positives (%) Negatives (%)
T=3months
Culture (N=305) Eradication 11 (7) 141 (93)
Placebo 99 (65) 54 (35)
H&E stains (N=305) Eradication 19 (12) 133 (88)
Placebo 112 (73) 41 (27)
IHC stains (N=68) Eradication 29 (85) 5 (15)
Placebo 7 (20) 27 (79)
Serology (N=203) Eradication 92 (91) 9 (9)
Placebo 94 (92) 8 (8)
T=12months
Serology (N=304) Eradication 96 (64) 55 (36)
Placebo 138 (90) 15 (10)
H&E: hematoxylin and eosin, IHC: immunohistochemistry. Positive serology
was defined as H. pylori IgG-antibody titers ≥ 250 IU/mL.baseline characteristics as the whole population, data
not shown) of 68 patients in which IHC stains were per-
formed, 29 (85%) of the 34 patients who had been trea-
ted with H. pylori eradication therapy had a negative
IHC stain, compared to 7 (21%) of the 34 patients in the
placebo group (P < 0.001). There were no differences be-
tween patients using gastroprotection compared to
patients who did not take gastroprotective drugs for the
presence of H. pylori by culture or histology (p = 0.454).
According to the gold standard criteria, a patient could
be either H. pylori positive or H. pylori negative. The
sensitivity, specificity, positive predictive values (PPV)
and negative predictive values (NPV) of each test were
calculated for the whole group and also differentiated
for preceding H. pylori eradication therapy or placebo,
as is shown in Table 2. For the combined analysis of
H&E and IHC stains, results were positive if either test
was positive or results were negative if both tests were
negative. According to the gold standard criteria for H.
pylori infection, H. pylori eradication was successful in
133 (89.9%) of the 148 patients who had been treated
with H. pylori eradication therapy, while 120 (78.9%) of
the 152 patients who had been receiving placebo
remained H. pylori positive. Gold standard criteria could
not be calculated in 4 patients in the eradication group
en 1 in the placebo group because of missing or negativeEradication 73 100 100 97
Placebo 83 100 100 62
H&E stains
Total 93 99 99 94
Eradication 93 99 93 99
Placebo 92 100 100 78
Subgroup of 68 patients
IHC stains
Total 100 95 94 100
Eradication 100 94 60 100
Placebo 100 100 100 100
H&E+IHC
Total 100 92 91 100
Eradication 100 90 50 100
Placebo 100 100 100 100
H&E: hematoxylin and eosin, IHC: immunohistochemistry.
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with available histology results.
Serology
At baseline, H. pylori IgG-antibody titers varied from
250 IU/mL to 19029 IU/mL with a median of 1689 IU/
mL (interquartile range (IQR) 700 to 3732 IU/mL) with
no significant differences in titers between the groups
assigned to H. pylori eradication therapy or to placebo
(P = 0.39). At endoscopy at 3 months, H. pylori IgG-
antibody titers varied from 126 IU/mL to 12800 IU/mL,
with a median of 1190 IU/mL (IQR 500 to 2820 IU/mL).
Patients who had been treated with H. pylori eradication
therapy had lower H. pylori IgG-antibody titers than
those treated with placebo; eradication group (n = 101)
median 730 IU/mL (IQR 415 to 1461 IU/mL) and pla-
cebo group (n = 102) median 2026 IU/mL (IQR 700 to
3571 IU/mL) (median difference −907, 95% CI −1356 to
−460, P < 0.001 Figure 1). At serological testing at
12 months, patients who had been treated with H. pylori
eradication therapy had lower H. pylori IgG-antibody
titers than those treated with placebo; eradication group
(n = 151) median 370 IU/mL (IQR 200 to 672 IU/mL)
and placebo group (n = 153) median 1340 IU/mL (IQR
490 to 3272 IU/mL) (median difference −778, 95% CI
−1128 to −466, P < 0.001 Figure 1).
At 3 months, H. pylori IgG-antibody titers had
dropped below the 250 IU/mL threshold for positivity in
17/203 (8.4%) patients; 9/101 (9%) in the eradication
group and 8/102 (8%) in the placebo group (P= 0.78). At
12 months, H. pylori IgG-antibody titers had droppedFigure 1 Median (black diamond) and interquartile range (grey
line) of H. pylori IgG-antibody titers in IU/mL for the eradication
and placebo groups, at baseline, 3 months and 12 months
after eradication therapy.below the 250 IU/mL threshold for positivity in 70/304
(23%) patients; 55/151 (36%) in the eradication group
and 15/153 (10%) in the placebo group (P < 0.05),
Table 1.
The absolute change in H. pylori IgG-antibody titers
from baseline to 3 months (titer at baseline minus titer
at 3 months) did differ significantly between the groups;
eradication group median change 980 IU/mL (IQR 190
to 2720 IU/mL) and placebo group median change
−26 IU/mL (IQR −605 (elevation of titer) to 870 IU/mL)
(median difference 1006, 95% CI 654 to 1471, P< 0.001).
The change in H. pylori IgG-antibody titers from base-
line to 12 months also differed significantly between the
groups; eradication group median change 1010 IU/mL
(IQR 363 to 2917 IU/mL) and placebo group median
change 167 IU/mL (IQR −337 (elevation of titer) to
1625 IU/mL) (median difference 913, 95% CI 547 to
1362, P < 0.001).
Compared to baseline, at 3 monthsH. pylori IgG-
antibody titers were median 55% lower (IQR 24% to
72%) in the eradication group and median 0.9% lower
(IQR −32% to 40%) in the placebo group (median differ-
ence 46%, 95% CI 34% to 60%, P < 0.001). Compared to
baseline, at 12 monthsH. pylori IgG-antibody titers were
median 77 % lower (IQR 48% to 88%) in the eradication
group and median 22 % lower (IQR −34% to 56%) in the
placebo group (median difference 46%, 95% CI 36 to 58,
P < 0.001).
Using the predefined H. pylori IgG-antibody titer cut-
off point of ≥250 IU/mL, serological testing for H. pylori
IgG-antibodies at endoscopy at 3 months was found to
be highly sensitive (99%) but with very poor specificity
(15%), especially following H. pylori eradication therapy
(10%). Arguably, the absolute or percent change in H.
pylori IgG-antibody titers from baseline represent better
methods for evaluating success of H. pylori eradication.
Figure 2 presents the Receiver Operating Characteristic
(ROC) curves for absolute and percent change in H. pyl-
ori IgG-antibody titers after 3 and 12 months, associated
with a negative result for the gold standard criteria for
H. pylori infection. Percent change scores had better
diagnostic power in identifying H. pylori negative
patients at both 3 and 12 months, with area under the
ROC curves (AUCs) of 0.62 (95% CI 0.52 to 0.72,
P= 0.343) for absolute change and 0.70 (95% CI 0.59 to
0.79, P= 0.085) for percent change at 3 months and 0.73
(95% CI 0.65 to 0.80, P= 0.0016) for absolute change
and 0.83 (95% CI 0.76 to 0.89, P < 0.0001) for percent
change at 12 months. The optimal cut-off point at
3 months for percent change in H. pylori IgG-antibody
titers was 21 %, corresponding to a sensitivity of 64%
(95% CI 31% to 89%) and specificity of 81% (95% CI 71%
to 89%), negative Likelihood ratio 0.45 (95% CI 0.2 to
1.1), positive Likelihood ratio 3.3 (95% CI 2.1 to 5.2).
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Figure 2 Comparison of ROC curves for absolute and percent change of H. pylori-IgG antibody titers at 3 and 12 months after
eradication therapy.
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change in H. pylori IgG-antibody titers was 58%, corre-
sponding to a sensitivity of 87% (95% CI 60% to 98%)
and specificity of 74% (95% CI 65% to 81%), negative
Likelihood ratio 0.18 (95% CI 0.05 to 0.7), positive Like-
lihood ratio 3.3 (95% CI 2.6 to 4.1).
Discussion
Following H. pylori eradication therapy or placebo,
histological examination of gastric mucosal tissue biop-
sies provided good sensitivity and specificity ratios for
evaluating success of H. pylori eradication therapy. In
the subgroup with both IHC and H&E staining, IHC
was slightly superior to H&E. Following eradication ther-
apy both staining methods provided 100% sensitivity and
also very high specificity. A combined analysis of H&E
and IHC stains, in which results were positive if either
test was positive or results were negative if both tests
were negative, did not improve sensitivity while the
number of false positive test results increased. Culture of
H. pylori in gastric biopsy specimens has very high spe-
cificity but relatively low sensitivity [5,32]. In the present
study, culture provided 100% specificity and 82% sensi-
tivity. However, after H. pylori eradication therapy sensi-
tivity dropped to 73% due to an increasing percentage of
false negative cultures. Culture of H. pylori therefore
does not appear to be very useful for evaluating success
of H. pylori eradication therapy. In clinical practice, inva-
sive tests for confirmation of eradication should only be
used in cases where repeat endoscopy is indicated, for
example in patients with gastric ulcer. In all other cases
non-invasive test should be employed for follow-up after
H. pylori eradication treatment [33].
The choice of a gold standard affects test results of all
other tests. According to the guidelines for clinical trials
in H. pylori infection, a reliable gold standard shouldconsist of at least 2 methods based on different princi-
ples for detecting H. pylori infection [5,34]. In the
present study, a patient was also considered H. pylori
positive if culture alone was positive, in view of its abso-
lute specificity. The gold standard in the present study
corresponds to acceptable criteria.
Other accurate and relatively inexpensive non-invasive
tests that may also be considered for the evaluation of
success of H. pylori eradication therapy are serology,
13C-urea breath tests and stool antigen tests [33]. While
the 13C-urea breath test may have better accuracy
(>90%), the serology test used in this study was less ex-
pensive and readily available in all study centres [35]. At
the time of the study, stool antigen tests were not yet
widely available in the Netherlands. PPI usage (in this
study 48 % of the population) may result in false nega-
tive test results in both invasive and non-invasive tests,
such as culture, histology and 13C-urea breath testing,
and should therefore be stopped two weeks before test-
ing [36]. This does not apply for serological testing. Be-
sides, stopping PPI in a population of chronic NSAID
users would be non-ethical in a trial setting.
This study shows that in NSAID users, percent change
in H. pylori IgG-antibody titers has better diagnostic
power in identifying H. pylori negative patients at both 3
and 12 months than absolute change in H. pylori IgG-
antibody titers. Repeated serological testing using a cut-
off point of 21% decrease in H. pylori IgG-antibody titers
after 3 months and 58% after 12 months has sufficiently
high sensitivity and specificity to be useful for evaluating
the success of H. pylori eradication therapy. Other
groups have found high sensitivity and specificity ratios
for percent decrease in H. pylori IgG-antibody titers
using cut-off points of 25% at 6 months and 40% at 3 to
6 months [10,11,37]. Using a predefined H. pylori IgG-
antibody titer cut-off point of 250 IU/mL, repeated
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found to have little diagnostic value.
Overall, NSAID use did not seem to influence H. pyl-
ori eradication rates or serological testing for H. pylori
IgG-antibodies, when compared to other studies with
patients who do not take NSAIDs [5,32]. Although stud-
ies on H. pylori IgG serology are not new, there is some
data available in which has been shown that NSAID
treatment significantly decreases the degree of gastric in-
flammation [22-25]. However in some studies aspirin
and NSAID possibly suppresses the growth of H. pylori
and may influence diagnostic testing and increase its
susceptibility to the antibiotics [38-40]. It is therefore
possible that in patients with H. pylori infection, concur-
rent NSAID treatment may affect levels of gastric in-
flammation and may consequently affect the serological
response. While several studies have investigated the
time course of H. pylori antibody titers after H. pylori
eradication therapy, none have been conducted in
NSAID users yet. Theoretically, if NSAID treatment
decreases the degree of gastric inflammation and subse-
quently affects the serological response, one would not
expect to find many false positive test results. However,
such an effect still cannot be ruled out because in the
present study, a relatively strong decline in H. pylori
IgG-antibodies was noted 3 months after H. pylori eradi-
cation (median 55% decline at 3 months and median
77% decline at 12 months), compared to other studies. A
previous longitudinal analysis of H. pylori IgG-antibody
titers following successful H. pylori eradication demon-
strated a mean decline of 26% at 3 months, 43% at
6 months, and 55% at nine months follow-up, after
which titers appeared to plateau at approximately 50%
compared to baseline [28].
Conclusions
In the present study in NSAID taking patients, following
H. pylori eradication therapy or placebo, histological
examination of gastric mucosal tissue biopsies provided
good sensitivity and specificity ratios. The H&E and IHC
staining methods provided comparable high sensitivity
and specificity but combining IHC and H&E did not im-
prove results. A percentual H. pylori IgG-antibody titer
change has better sensitivity and specificity than an ab-
solute titer change or a predefined H. pylori IgG-
antibody titer cut-off point for evaluating success of H.
pylori eradication therapy.
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